BioVie President & CEO Cuong Do joins Natalie Stoberman from the Proactive studio to share how its NE3107 molecule from Alzheimer's and Parkinson's Disease treatment research is suggesting BioVie's technology has an impact on improving patients’ DNA methylation profiles, potentially impacting biological aging.
BioVie is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. For more information visit https://bioviepharma.com/